Showing 3 results for Drug Delivery Systems
Saba Mehrandish, Shahla Mirzaee,
Volume 9, Issue 4 (1-2019)
Abstract
Fungi are eukaryotic organisms that potentially have the ability to cause disease in humans and animals. Fungal infections are called mycosis, which are divided into four types of superficial, cutaneous, subcutaneous and systemic, depending on the area of the body involved. Though cutaneous mycoses are rarely life-threatening infections, they can isolate the patient socially due to the disfigurement of the tissues they caused, as a result of which, treatment has always been an important issue. On the other hand the similarity of fungi to mammalian cells led to difficulties in the development of novel antifungal drugs. Consequently, in recent years, extensive efforts have been made to design and develop novel drug delivery systems with better efficacy for drug delivery of conventional anti-fungal drugs. In this study, we compared conventional forms and novel drug delivery systems of a number of antifungal drugs. All studies confirm the relative priority of novel drug delivery systems to conventional forms in terms of penetration, release, and antifungal effects.
Fatemeh Yazdani Hamid,
Volume 13, Issue 2 (8-2022)
Abstract
Skin cancers are highly prevalent malignancies that affect millions of people worldwide. These include melanomas and nonmelanoma skin cancers. Melanomas are among the most dangerous cancers, while nonmelanoma skin cancers generally exhibit a more benign clinical pattern; however, they may sometimes be aggressive and metastatic.
Melanomas typically appear in body regions exposed to the sun, although they may also appear in areas that do not usually get sun exposure. Thus, their development is multifactorial, comprising endogenous and exogenous risk factors. The management of skin cancer depends on the type; it is usually based on surgery, chemotherapy, immunotherapy, and targeted therapy. In this respect, oncological treatments have demonstrated some progress in the last years; however, current therapies still present various disadvantages such as little cell specificity, recurrent relapses, high toxicity, and increased costs. Furthermore, the pursuit of novel medications is expensive, and the authorization for their clinical utilization may take 10-15 years. Thus, repositioning of drugs previously approved and utilized for other diseases has emerged as an excellent alternative. In this mini-review, we aimed to provide an updated overview of drugs’ repurposing to treat skin cancer and discuss future perspectives.
Faezeh Roshanbakht, Nahid Hassanzadeh Nemati, Neda Attaran Kakhki,
Volume 16, Issue 1 (5-2025)
Abstract
Skin infections caused by pathogenic bacteria such as Staphylococcus aureus and Pseudomonas aeruginosa have become a serious challenge in the field of antibacterial therapies, especially in the context of antibiotic resistance. In this regard, the simultaneous use of classical antibiotic combinations with advanced nanostructures is considered a novel and effective approach. Narasin, an ionophore antibiotic of natural origin, has a high potential in inhibiting bacterial growth due to its ability to disrupt cell membrane function and ion transport. On the other hand, silica nanostructures, especially mesoporous silica nanoparticles, play an important role in enhancing antibacterial activity due to their properties such as biocompatibility, drug loading capability, controlled release, and production of reactive oxygen species.
Recent studies have shown that the combination of narasin with silica nanostructures enhances the synergistic antibacterial effects, increases drug stability, and improves penetration into bacterial biofilms. This combination has also been effective in reducing the dosage and systemic toxicity. Despite promising results in laboratory and animal models, challenges such as the assessment of cytotoxicity, precise release control, and the need for extensive clinical studies remain.
In this article, while comprehensively reviewing the properties and functions of narasin and silica nanostructures, the mechanisms of their combined effects on skin pathogenic bacteria are discussed and future prospects in the development of nanobiotechnological therapies are reviewed.
